efficacy and tolerance of liraglutide for weight loss in obese type 2 diabetic hemodialysis patients

Conditions: Diabetes Mellitus, Type 2; Hemodialysis; Obese

Summary: diabetes is the second leading cause of end stage renal disease in france (22% in the 2016 rein register). in hemodialysis, its prevalence is higher, between 30-40% depending on the study. associated with type 2 diabetes, a large number of patients present with overweight (body mass index or bmi\> 25 kg / m2) which can lead to a temporary contraindication to kidney transplant by the surgeon, or even definitive once bmi is over 30 kg / m2. indeed, above this threshold, patients are exposed to an increased risk of surgical complications (wall infections, suture release), hospitalizations and potentially transplant failure. a recent study based on the kidney registry showed that patients with a bmi\> 31 kg / m2 were more likely to stay on dialysis than to benefit from a transplant whereas for each decrease of 1 kg / m2 of bmi, there is a 9-11% increase in the likelihood of being transplanted. the management of obesity in dialysis patients is important for reducing cardiovascular risks but also because it increases the chances of access to transplantation. however, current weight loss programs are disappointing. the changes in hygiene and diet rules integrated into a specialized monitoring program only allow a weight loss of 2 to 8% in 24 months for half of the patients. bariatric surgery is, of course, a more effective alternative, but with a 10% risk of postoperative complications. glucagon-like peptide 1 (aglp1) analogues are a new class of antidiabetic drugs that have revolutionized the management of type 2 diabetes. in fact, they combine efficacy on glycemic control but also on weight loss. they are used in obese non-diabetic people in some countries, with a reduction in weight of up to 10 to 15% with certain molecules. in addition, they have shown an effect on reducing cardiovascular events in diabetics including with chronic kidney disease ckd 3-4. agpl1 are well tolerated with side effects mainly of digestive tropism such as nausea or vomiting. exceptionally, these effects can occur from the first injection requiring permanent discontinuation of treatment. in 20% of cases, these side effects can appear in the first weeks. they gradually fade, spontaneously or after symptomatic treatment and allow titration of the drug. aglp1 is currently contraindicated in patients with reduced renal function, that is, when the glomerular filtration rate (gfr) is \ 10 years) on its effectiveness and its short and long-term side effects. the main objective of this project, in type 2 diabetic patients on dialysis, as a temporary contraindication for transplant due to overweight, is on the one hand to study the effect of liraglutide on weight loss and control of diabetes, and on the other hand to assess its tolerance in this population. the expected benefit is to be able to facilitate registration on the waiting list and access to renal transplantation of these overweight patients, without having to resort to more invasive methods such as bariatric surgery.


Eligibility criteria:
inclusion criteria: * patient aged ≥ 18 and \<70 * patient on hemodialysis for more than 6 months * type 2 diabetic patient * patient with a bmi\> 30 kg / m2 with a temporary contraindication for kidney transplant for renal transplant due to overweight by his graft center * patient affiliated to a health insurance plan * french speaking patient * patient having given free, informed and written consent exclusion criteria: * patient with a temporary contraindication for kidney transplant for a cause other than overweight * patient with personal or family history of thyroid medullary cancer * patient with a history of acute or chronic pancreatitis * patient who has already had hypersensitivity to liraglutide (or to any other component of the product) * patient who has already had a severe digestive intolerance to taking glp-1 receptor agonists (such as exenatide or lixisenatide) * patient already included in an interventional risk research protocol (riph1) * pregnant or lactating woman * patient under guardianship or curatorship * patient deprived of liberty